Svetlana Nikic, Founder of Precision Oncology Consulting, shared a post on LinkedIn:
“Comprehensive genomic profiling (CGP) in advanced NSCLC continues to expose a clear testing–treatment gap.
In this Finnish real-world cohort from Tampere University Hospital (n=96), CGP identified clinically actionable alterations with EMA/FDA-approved targeted therapies in 45% of patients (43/96).
Of these, 42 were ESCAT I and 1 was ESCAT II. When TMB-high (≥10 mut/Mb, ESCAT I) was included, 66% of patients (63/96) harboured ESCAT I/II findings.
Yet only one third (33%) of those with actionable (ESCAT I/II) alterations actually received matched targeted therapy.
KRAS G12C, present in 18% of the cohort, remained largely untreated due to lack of reimbursed G12C inhibitors as well as other ESCAT I targeting agents (e.g. sotorasib, amivantamab, trastuzumab deruxtecan and dabrafenib-trametinib or encorafenibbinimetinib) by the Social Insurance Institution of Finland – there is an average 351-day lag from EMA approval to Finish national drug reimbursement.
For anyone working on CGP, this study is a strong reminder that sequencing alone is not enough. Without a robust, payer-oriented value story and timely reimbursement, many patients with clear actionable alterations will not receive the therapies their tumour biology supports. It also demonstrates that we need better alignment between biomarker testing and drug access.
If your organisation is currently advancing CGP and you need to articulate this value to HTA bodies and payers, I have put together a concise Case Study on “Unlocking access: building the reimbursement case for CGP” based on a project we’ve carried out from Precision Oncology Consulting for a leading global CGP developery. It covers unmet need and testing landscape, clinical value synthesis across major solid tumours, economic evidence, and how we translated this into a payer-ready global value dossier and negotiation narrative.
You can access the case study via the link below and if you would like to discuss how a tailored CGP value dossier or reimbursement strategy could support your programmes in Europe please message me or send me an email at [email protected].”
Title: Comprehensive Genomic Profiling in Advanced Non-Small Cell Lung Cancer: A Real-World Cohort Study in Finland
Authors: Kirsi Hormalainen, Kaisa Marttila, Matti Nykter, Toomas Uibu, Jarkko Ahvonen, Vidal Fey, Mauri Keinänen, Maarit Bärlund, Arja Jukkola
Read the Full Article.
More posts featuring Svetlana Nikic.